KLOW
Four-peptide research blend · Research-grade reference material
Identity
- Molecular formula
- N/A — 4-component combination preparation (GHK-Cu, BPC-157, TB-500, KPV; ratio 5:1:1:1)
- Molecular weight
- —
- CAS number
- —
Research Background
GHK-Cu is a naturally occurring copper-binding tripeptide, studied for stimulating collagen and connective tissue synthesis.
BPC-157 is a synthetic 15-amino-acid peptide studied primarily for angiogenesis, new blood vessel formation into damaged tissue.
TB-500 (Thymosin Beta-4) is a naturally occurring 43-amino-acid actin-sequestering protein studied for its role in directed cell migration during tissue repair.
KPV is the C-terminal tripeptide of alpha-MSH (residues 11-13), lacking the parent hormone’s melanocortin receptor-binding activity while retaining much of its anti-inflammatory signaling. It’s studied for blocking NF-κB activation through a receptor-independent, intracellular mechanism, entering cells via the PepT1 transporter (Brzoska et al.).
Lab-tested research material
Mechanism
KLOW takes the GLOW formulation and adds KPV specifically for its studied anti-inflammatory mechanism, the premise being that pairing tissue-building and repair-signaling compounds (GHK-Cu, BPC-157, TB-500) with an NF-κB-focused anti-inflammatory compound (KPV) addresses both the regenerative and inflammatory sides of tissue research simultaneously.
State of the Evidence
No study has tested this four-component combination directly. Each ingredient’s research record, including KPV’s NF-κB mechanism, reflects that compound studied in isolation. KPV specifically has no published randomized controlled human trial in any inflammatory condition; its evidence base is preclinical and mechanistic. The rationale for combining all four compounds is mechanistic reasoning, not a demonstrated combined or synergistic effect.
Reference: Brzoska, Tomasz, et al. “Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides.” Endocrine Reviews, vol. 29, no. 5, 2008, pp. 581-602.
The Blend Question — Read This Carefully
This is the single most important section in a blend document, and it is the one most often omitted. The constituents of this product have published preclinical literature. The combination does not.
Evidence at a glance
Evidence does not simply add up. Preclinical findings for KPV, GHK-Cu, BPC-157, TB-500 were generated with each compound administered alone, at defined doses in defined models. Combining the compounds does not combine their evidence bases.
Interactions are uncharacterized. Additive, synergistic and antagonistic effects between these constituents have not been systematically studied. Absence of reported interactions is not evidence of their absence.
Ratios are not standardized. Blend composition varies between suppliers and lots, so published work — and results from other vendors’ blends — are not directly transferable.
Attribution is confounded. An observed effect cannot be attributed to a single constituent without appropriate single-compound controls.
Design implication. Where mechanism matters, single-compound arms are necessary. A blend suits combination-effect questions, not characterization of any individual constituent.
Appropriate characterization: a multi-component research preparation whose constituents each carry preclinical literature, and whose combined behaviour is uncharacterized. Claims describing the blend as delivering the summed or amplified effects of its parts are not supported by published evidence.
Regulatory & status notes
Selected references
- 1. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
- 2. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences. 2026;16(12):6202.
- 3. Maquart FX, et al. Stimulation of collagen synthesis by GHK-Cu²⁺ in fibroblast cultures. FEBS Lett. 1988. PMID 3169264.
- 4. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. PMID 18092346.
Safety Information
Research-use preparation with limited human data on any individual component, and none on this specific four-component combination. Evidence strength varies — see the individual Registry entries for GHK-Cu, BPC-157, TB-500, and KPV.
No established clinical contraindications. This is an investigational combination with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician. For research and educational purposes only, not for human or veterinary use.
Related Compounds
For research and educational purposes only. Not for human or veterinary use.